logo-loader

Concepta aims to take stress out of conception

Published: 07:54 07 Feb 2017 EST

picture of pregnant woman
The aim of myLotus's kit

Concepta PLC (LON:CPT) has made good progress since it reversed into the cash shell formerly known as Frontier Resources.

The AIM-listed group raised £3.5mln as part of the float in July 2016 and with many of the hard yards developing its MyLotus fertility kit already completed, newsflow has been encouraging.

MyLotus, which will retail for £250-£300, has been developed for women who have been trying to conceive for six months or more.

It measures hormone levels in urine to give quantitative and qualitative measurements that might help explain the apparent lack of fertility.

 

China first then Europe

China will be the first commercial market as the registration process “took the least time”, chief executive Erik Henau told Proactive.

There it will be sold online to the emerging middle classes and via hospital pharmacies.

It will be promoted in hospitals using the Wi-Fi system, which will carry a MyLotus landing page, and the product will be supported via an app.

Concepta has already agreed terms with a distributor in the People’s Republic that has agreed to pay cash upfront when it places orders for the device.

In Europe, MyLotus is awaiting regulatory sign-off in the form of a CE Mark and is hoping to accomplish this shortly.

Here it will sell the product online as there is a fairly well defined, accessible potential user base that is well informed about fertility innovations.

 “Excitingly, Concepta has the opportunity to translate its proprietary platform into commercial success in these initial markets where annual revenues in the infertility segment are estimated to be worth around £600mln”.

In January, it achieved the ISO13485 management accreditation, which it says was a key step towards European regulatory approval.

Concepta wants to launch myLotus into the £350mln UK and Europe market in the second half of this year and the management accreditation will endorse its position as a medical device manufacturer, it said.

“The accreditation is recognised on an international scale and is a critical part of gaining regulatory approval for Concepta's myLotus to be sold in the European Union.”

Stress tests the next development

But the plans don’t stop there.

The next step will be a stress test to help both women and men with fertility problems.

A technology transfer and licence agreement has been agreed with Selective Antibodies, a UK based diagnostics company.

Concepta will be given exclusive rights to rights to Selective’s intellectual property in return for fees and a royalty on any products sold.

At present, the Lotus platform capabilities include measurements of a woman's personal hCG and LH hormone levels.

With Selective’s input, Concepta wants to expand this reach to quantitative measurement of stress hormones such as cortisol.

“Stress is a common cause of several health conditions and is widely recognised as a key factor, which can significantly impact both male and female fertility factors,” the company said. 

Henau added myLotus’s key differentiator is that users can quantify their personal results from home diagnostic tests.

 "We believe our myLotus platform opens the door to wider health monitoring at home to improve individual health parameters, seeing the real-time effects of medical interventions and using the data collected to adjust treatment accordingly.

 "As such, our first collaborative project, with Selective Antibodies, is focused on stress, which has a significant documented impact on both male and female fertility. 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

5 hours, 21 minutes ago